Community-acquired respiratory viruses in transplant patients: Diversity, impact, unmet clinical needs

Michael G. Ison*, Hans H. Hirsch

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Patients undergoing solid-organ transplantation (SOT) or allogeneic hematopoietic cell transplantation (HCT) are at increased risk for infectious complications. Community-acquired respiratory viruses (CARVs) pose a particular challenge due to the frequent exposure pre-, peri-, and posttransplantation. Although influenza A and B viruses have a top priority regarding prevention and treatment, recent molecular diagnostic tests detecting an array of other CARVs in real time have dramatically expanded our knowledge about the epidemiology, diversity, and impact of CARV infections in the general population and in allogeneic HCT and SOT patients. These data have demonstrated that non-influenza CARVs independently contribute to morbidity and mortality of transplant patients. However, effective vaccination and antiviral treatment is only emerging for non-influenza CARVs, placing emphasis on infection control and supportive measures. Here, we review the current knowledge about CARVs in SOT and allogeneic HCT patients to better define the magnitude of this unmet clinical need and to discuss some of the lessons learned from human influenza virus, respiratory syncytial virus, parainflu-enzavirus, rhinovirus, coronavirus, adenovirus, and bocavirus regarding diagnosis, prevention, and treatment.

Original languageEnglish (US)
Article numbere00042
JournalClinical microbiology reviews
Volume32
Issue number4
DOIs
StatePublished - Jan 1 2019

Fingerprint

Viruses
Cell Transplantation
Transplants
Organ Transplantation
Bocavirus
Influenza B virus
Community-Acquired Infections
Rhinovirus
Coronavirus
Respiratory Syncytial Viruses
Molecular Pathology
Influenza A virus
Virus Diseases
Infection Control
Orthomyxoviridae
Routine Diagnostic Tests
Adenoviridae
Respiratory Tract Infections
Human Influenza
Antiviral Agents

Keywords

  • Bone marrow transplantation
  • Diagnosis
  • Respiratory viruses
  • Solid-organ transplantation
  • Treatment
  • Vaccination

ASJC Scopus subject areas

  • Epidemiology
  • Immunology and Microbiology(all)
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{96dc0d74352f4120b69ddc622932538a,
title = "Community-acquired respiratory viruses in transplant patients: Diversity, impact, unmet clinical needs",
abstract = "Patients undergoing solid-organ transplantation (SOT) or allogeneic hematopoietic cell transplantation (HCT) are at increased risk for infectious complications. Community-acquired respiratory viruses (CARVs) pose a particular challenge due to the frequent exposure pre-, peri-, and posttransplantation. Although influenza A and B viruses have a top priority regarding prevention and treatment, recent molecular diagnostic tests detecting an array of other CARVs in real time have dramatically expanded our knowledge about the epidemiology, diversity, and impact of CARV infections in the general population and in allogeneic HCT and SOT patients. These data have demonstrated that non-influenza CARVs independently contribute to morbidity and mortality of transplant patients. However, effective vaccination and antiviral treatment is only emerging for non-influenza CARVs, placing emphasis on infection control and supportive measures. Here, we review the current knowledge about CARVs in SOT and allogeneic HCT patients to better define the magnitude of this unmet clinical need and to discuss some of the lessons learned from human influenza virus, respiratory syncytial virus, parainflu-enzavirus, rhinovirus, coronavirus, adenovirus, and bocavirus regarding diagnosis, prevention, and treatment.",
keywords = "Bone marrow transplantation, Diagnosis, Respiratory viruses, Solid-organ transplantation, Treatment, Vaccination",
author = "Ison, {Michael G.} and Hirsch, {Hans H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1128/CMR.00042-19",
language = "English (US)",
volume = "32",
journal = "Clinical Microbiology Reviews",
issn = "0893-8512",
publisher = "American Society for Microbiology",
number = "4",

}

Community-acquired respiratory viruses in transplant patients : Diversity, impact, unmet clinical needs. / Ison, Michael G.; Hirsch, Hans H.

In: Clinical microbiology reviews, Vol. 32, No. 4, e00042, 01.01.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Community-acquired respiratory viruses in transplant patients

T2 - Diversity, impact, unmet clinical needs

AU - Ison, Michael G.

AU - Hirsch, Hans H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients undergoing solid-organ transplantation (SOT) or allogeneic hematopoietic cell transplantation (HCT) are at increased risk for infectious complications. Community-acquired respiratory viruses (CARVs) pose a particular challenge due to the frequent exposure pre-, peri-, and posttransplantation. Although influenza A and B viruses have a top priority regarding prevention and treatment, recent molecular diagnostic tests detecting an array of other CARVs in real time have dramatically expanded our knowledge about the epidemiology, diversity, and impact of CARV infections in the general population and in allogeneic HCT and SOT patients. These data have demonstrated that non-influenza CARVs independently contribute to morbidity and mortality of transplant patients. However, effective vaccination and antiviral treatment is only emerging for non-influenza CARVs, placing emphasis on infection control and supportive measures. Here, we review the current knowledge about CARVs in SOT and allogeneic HCT patients to better define the magnitude of this unmet clinical need and to discuss some of the lessons learned from human influenza virus, respiratory syncytial virus, parainflu-enzavirus, rhinovirus, coronavirus, adenovirus, and bocavirus regarding diagnosis, prevention, and treatment.

AB - Patients undergoing solid-organ transplantation (SOT) or allogeneic hematopoietic cell transplantation (HCT) are at increased risk for infectious complications. Community-acquired respiratory viruses (CARVs) pose a particular challenge due to the frequent exposure pre-, peri-, and posttransplantation. Although influenza A and B viruses have a top priority regarding prevention and treatment, recent molecular diagnostic tests detecting an array of other CARVs in real time have dramatically expanded our knowledge about the epidemiology, diversity, and impact of CARV infections in the general population and in allogeneic HCT and SOT patients. These data have demonstrated that non-influenza CARVs independently contribute to morbidity and mortality of transplant patients. However, effective vaccination and antiviral treatment is only emerging for non-influenza CARVs, placing emphasis on infection control and supportive measures. Here, we review the current knowledge about CARVs in SOT and allogeneic HCT patients to better define the magnitude of this unmet clinical need and to discuss some of the lessons learned from human influenza virus, respiratory syncytial virus, parainflu-enzavirus, rhinovirus, coronavirus, adenovirus, and bocavirus regarding diagnosis, prevention, and treatment.

KW - Bone marrow transplantation

KW - Diagnosis

KW - Respiratory viruses

KW - Solid-organ transplantation

KW - Treatment

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85072104181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072104181&partnerID=8YFLogxK

U2 - 10.1128/CMR.00042-19

DO - 10.1128/CMR.00042-19

M3 - Review article

C2 - 31511250

AN - SCOPUS:85072104181

VL - 32

JO - Clinical Microbiology Reviews

JF - Clinical Microbiology Reviews

SN - 0893-8512

IS - 4

M1 - e00042

ER -